StreetInsider.com News Articles

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

- Video webcast now available here

HOUSTON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it participated in the Virtual Investor “Why Now” on-demand conference.

During the presentation, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, highlighted the Company's clinical progress and long-term opportunity, discussing encouraging interim results from the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML). The presentation also emphasized Annamycin's differentiated clinical

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

- Video webcast now available here

Form SCHEDULE 13D Moleculin Biotech, Inc. Filed by: Foster Jonathan P.

Tue, 25 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260825/26975058.html

Form SCHEDULE 13D Moleculin Biotech, Inc. Filed by: Foster Jonathan P.

Tue, 25 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260825/26975058.html

Form SCHEDULE 13D Moleculin Biotech, Inc. Filed by: KLEMP WALTER V

Tue, 25 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260825/26975042.html

Form SCHEDULE 13D Moleculin Biotech, Inc. Filed by: KLEMP WALTER V

Tue, 25 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260825/26975042.html

Form DEFA14A Moleculin Biotech, Inc.

Mon, 24 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260824/26969069.html

Form DEFA14A Moleculin Biotech, Inc.

Mon, 24 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260824/26969069.html

Form DEF 14A Moleculin Biotech, Inc. For: Oct 09

Mon, 24 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26968985.html

Form DEF 14A Moleculin Biotech, Inc. For: Oct 09

Mon, 24 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26968985.html

Form 424B5 Moleculin Biotech, Inc.

Fri, 21 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260821/26962470.html

Form 424B5 Moleculin Biotech, Inc.

Fri, 21 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260821/26962470.html

Form PRE 14A Moleculin Biotech, Inc. For: Oct 09

Fri, 14 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260814/26932617.html

Form PRE 14A Moleculin Biotech, Inc. For: Oct 09

Fri, 14 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260814/26932617.html

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Fri, 14 Aug 2026 08:30:00 -0400

Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML
MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the unblinded efficacy readout in December 2026 to February 2027 timeframe
MIRACLE trial Part B initiation expected in the first half of 2027 following optimal dose selection
Cash position, including $9.3 million raised after quarter-end, expected to fund operations into the first quarter of 2027
Absence of cardiotoxicity continues in the MIRACLE trial

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE)

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Fri, 14 Aug 2026 08:30:00 -0400

Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML
MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the unblinded efficacy readout in December 2026 to February 2027 timeframe
MIRACLE trial Part B initiation expected in the first half of 2027 following optimal dose selection
Cash position, including $9.3 million raised after quarter-end, expected to fund operations into the first quarter of 2027
Absence of cardiotoxicity continues in the MIRACLE trial

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE)

Form 8-K Moleculin Biotech, Inc. For: Aug 14

Fri, 14 Aug 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260814/26925155.html

Form 8-K Moleculin Biotech, Inc. For: Aug 14

Fri, 14 Aug 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260814/26925155.html

Form 10-Q Moleculin Biotech, Inc. For: Jun 30

Thu, 13 Aug 2026 16:18:00 -0400
si-local-file:///var/storage/secattach/20260813/26921460.html

Form 10-Q Moleculin Biotech, Inc. For: Jun 30

Thu, 13 Aug 2026 16:18:00 -0400
si-local-file:///var/storage/secattach/20260813/26921460.html

Form SCHEDULE 13G Moleculin Biotech, Inc. Filed by: CVI Investments, Inc.

Mon, 10 Aug 2026 18:37:00 -0400
si-local-file:///var/storage/secattach/20260810/26899538.html

Form SCHEDULE 13G Moleculin Biotech, Inc. Filed by: CVI Investments, Inc.

Mon, 10 Aug 2026 18:37:00 -0400
si-local-file:///var/storage/secattach/20260810/26899538.html

Form SCHEDULE 13G Moleculin Biotech, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Thu, 06 Aug 2026 17:27:00 -0400
si-local-file:///var/storage/secattach/20260806/26885680.html

Form SCHEDULE 13G Moleculin Biotech, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Thu, 06 Aug 2026 17:27:00 -0400
si-local-file:///var/storage/secattach/20260806/26885680.html

Form 4 Moleculin Biotech, Inc. For: Aug 03 Filed by: KLEMP WALTER V

Wed, 05 Aug 2026 16:17:00 -0400
si-local-file:///var/storage/secattach/20260805/26874607.html